Despite this, the significant and robust reduction in HA-tag+ liver cancer specifically in Akt-YAP1 Sox9 iKO livers indicates the context- and oncogenic driver-dependent therapeutic potential of Sox9 elimination in advanced Akt-driven cHCC-CCA tumors (Figure 7F). This evidence concerns the gene SOX9 and cholangiocarcinoma.